#United States #Innovation #healthcare #Reckitt #Nutley, New Jersey

Reckitt's Landmark Investment in U.S. Operations

In a bold move to bolster its operations in the United States, Reckitt has announced a transformative investment of up to $600 million. This multi-year initiative focuses on enhancing both innovation and accessibility to healthcare products across the nation. The company's extensive plans include significant upgrades to two key locations that will impact thousands of employees and millions of consumers.

Strategic Focus Areas

Reckitt has identified critical areas for investment that will drive long-term growth in its U.S. business. The company's strategy revolves around the integration of its commercial capabilities and research development (R&D) efforts at a consolidated North American campus in New Jersey. This relocation aims to centralize operations, fostering collaboration and innovation in a state-of-the-art environment.

Furthermore, Reckitt is doubling down on its production capabilities, particularly at its manufacturing facility in North Carolina. The investment will allow this site to become the largest over-the-counter (OTC) manufacturing facility for the company in the U.S. by expanding production capacities for popular products such as Mucinex® and Move Free®. This facility is anticipated to begin operations in the first half of 2027.

Accelerating Innovation

Reckitt's emphasis on innovation is evident in its plans to construct a new science and innovation center in New Jersey. This center is designed to be a global hub for germ protection, significantly enhancing Reckitt's existing R&D capabilities. By blending advanced scientific expertise with commercial insights, Reckitt aims to expedite the journey from product conception to market availability. Dr. Angela Naef, Chief R&D Officer at Reckitt, emphasized that this investment will empower the company to respond quickly to evolving consumer needs, developing science-led solutions that can scale globally.

Reinforcing Supply Resilience

The company's commitment to reinforcing supply chain resilience is another key element of this investment initiative. By improving manufacturing flexibility and expanding facilities, Reckitt aims to ensure a reliable supply of healthcare products to consumers. This strategic move is not only about increasing production volume; it’s also a proactive measure against potential disruptions in the supply chain.

With over 4,000 employees spread across several manufacturing sites and innovation centers in the U.S., Reckitt has a rich history in American healthcare. With brands like Lysol® and Mucinex® trusted by generations, the company’s long-term presence in the U.S. is significant. Jérôme Lemaire, President of Reckitt North America, highlighted how these investments will enhance scientific leadership and further empower the accessibility of health products for American families.

Looking Ahead

On November 19th, Reckitt will host its first “Reckitt Focus On” event in the United States, where company leaders will showcase these exciting developments and the future of Reckitt in North America. This event promises to provide insights into how Reckitt plans to leverage this investment for growth and consumer benefit.

In recent years, Reckitt has proven itself as a world-class consumer health and hygiene company, dedicated to delivering better health solutions every day. As it undertakes this substantial investment, Reckitt continues its legacy of innovation and commitment to consumer welfare, helping millions achieve better health outcomes through trusted brands and effective products.

As they move forward, Reckitt’s investment in their U.S. operations stands as a testament to their dedication to ensuring that quality healthcare products are accessible, dependable, and innovative for generations to come.